Trials / Recruiting
RecruitingNCT05635266
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 20,000 (estimated)
- Sponsor
- Sanguine Biosciences · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
Conditions
- Age-Related Macular Degeneration
- Allergies
- Alpha-Gal Syndrome
- Alzheimer Disease
- Amyloidosis
- Ankylosing Spondylitis
- Arthritis
- Alopecia Areata
- Asthma
- Atopic Dermatitis
- Autism
- Autoimmune Hepatitis
- Behcet's Disease
- Beta-Thalassemia
- Cancer
- Celiac Disease
- Kidney Diseases
- COPD
- Crohn Disease
- Cystic Fibrosis
- Diabetes
- Dravet Syndrome
- DMD
- Fibromyalgia
- Graves Disease
- Thyroid Diseases
- Hepatitis
- Hidradenitis Suppurativa
- ITP
- Leukemia
- ALS
- Lupus or SLE
- Lymphoma
- Multiple Sclerosis
- Myasthenia Gravis
- Heart Diseases
- Parkinson Disease
- Pemphigus Vulgaris
- Cirrhosis
- Psoriasis
- Schizophrenia
- Scleroderma
- Sickle Cell Disease
- Stroke
- Ulcerative Colitis
- Vasculitis
- Vitiligo
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Specimen sample | The study may require a tissue collection and/or a participant survey for participation. Most tissue collected will come from a blood draw; up to 100mL for the health condition group, 60mL for the exceptive condition group, and up to 180mL for the control group (if determined safe for the participant). Participant surveys may involve participant reported outcomes (PROs) or custom participant surveys. |
Timeline
- Start date
- 2021-10-26
- Primary completion
- 2025-10-01
- Completion
- 2025-10-01
- First posted
- 2022-12-02
- Last updated
- 2024-05-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05635266. Inclusion in this directory is not an endorsement.